Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: Data from the AT.LANTUS trial

Diabetes, Obesity and Metabolism

Volumn 12, Issue 8, 2010, Pages 683-688

  Khunti, K ^a   Srinivasan, B T ^a,b   Shutler, S ^c   Davies, M J ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c NONE

Author keywords

Blood glucose; Glargine; Obesity; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE;

ADULT; ARTICLE; BEDTIME DOSAGE; BODY MASS; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POST HOC ANALYSIS; SELF CARE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; WEIGHT CONTROL; WEIGHT GAIN;

EID: 77958110347     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01217.x     Document Type: Article

References (22)

1. Turner RC, Holman RR, Stratton IM et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes; a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32: 193-203.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012
4. Yki-Jarvinen H, Ryysy L, Kauppila M et al. Effect of obesity on the response to insulin therapy in non insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 4037-4043.
5. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
6. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-767.
7. de Boer H, Keizers R, Jansen M, Verschoor L, Ruineman-Koerts J. Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen. Diabetes Obes Metab 2006; 8: 517-523.
8. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991; 90: 450-459.
9. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomised addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
10. Hermansen K, Davies M, Derezinski T, Ravn G, Clauson P, Home P. A 26-week randomized, parallel, treat-to-target trial comparing Insulin Detemir with NPHH Insulin as add-on therapy to oral glucose-lowering drugs in Insulin-Naïve people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
11. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. AT.LANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
12. World Health Organisation. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. Geneva, Switzerland, 1999.
13. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
14. Holman RR, Sanjoy PK, Bethel A, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM 2008; 359: 1577-1578.
15. Fritsche A, Haring H. At last, a weight neutral insulin? Int J Obes Relat Metab Disord 2004; 28: S41-S46.
16. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann.Intern.Med 1999; 130: 389-396.
17. Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity-onset diabetes: tablets or insulin? Br Med J 1984; 288: 1956-1959.
18. Vessby B, Bober M, Hellsing K, Lithell H, Berne C. C-peptide but not insulin concentrations are related to the serum lipoprotin levels during insulin treatment of non-insulin-dependent diabetes mellitus (NIDDM) patients. Diabetes Res 1989; 12: 109-116.
19. Hovarth K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, Issue 2, Art. No.: CD005613. DOI:10.1002/14651858.
20. Khunti K, Davies M. Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes, Obesity and Metabolism 2009. (doi: 10.1111/j.1463-1326.2009.01186.x
21. Massi BM, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone Metabolism Research 2003; 35: 189-196.
22. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch.Intern.Med 2001; 161: 1653-1659.